You are here

eczema

Dermira shares double on positive eczema data

Dermira shares double on positive eczema data

Biopharma Dive

clinical trials

Flag link:

Upcoming events – Ascendis and Lilly hope for growth with pivotal data

Upcoming events – Ascendis and Lilly hope for growth with pivotal data

EP Vantage

clinical trials

pediatric growth hormone deficiency

Flag link:

Hoth Therapeutics seeks IPO cash to battle eczema

Hoth Therapeutics seeks IPO cash to battle eczema

Fierce Biotech

Hoth Therapeutics

Flag link:

Sanofi unveils eczema drug data, as regulators mull label expansion

Sanofi unveils eczema drug data, as regulators mull label expansion

Pharmaforum

atopic dermatitis

Flag link:

Zai Lab bombs Phase IIa trial in atopic dermatitis, junks the program to shift resources to the pipeline

Zai Lab bombs Phase IIa trial in atopic dermatitis, junks the program to shift resources to the pipeline

Endpoints

clinical trials

Flag link:

2 Biotech Stocks Near All-Time Highs: Can They Keep Climbing?

2 Biotech Stocks Near All-Time Highs: Can They Keep Climbing?

Motley Fool

Flag link:

Sanofi and Regeneron's Dupixent launch is about to get a cash infusion

Sanofi and Regeneron's Dupixent launch is about to get a cash infusion

Fierce Pharma

Flag link:

Pfizer's Eucrisa beats Dupixent to the DTC punch in eczema, thanks to first-to-market status

Pfizer's Eucrisa beats Dupixent to the DTC punch in eczema, thanks to first-to-market status

Fierce Pharma

Flag link:

Dermira Commits $135M for Global Rights to Roche Eczema Drug

Dermira Commits $135M for Global Rights to Roche Eczema Drug

Xconomy

Flag link:

Sanofi's eczema rollout Dupixent hits blockbuster launch trajectory as earnings beat

Sanofi's eczema rollout Dupixent hits blockbuster launch trajectory as earnings beat

Fierce Pharma

Flag link:

Analyst: Payer hurdles hit dispense rates on Sanofi and Regeneron's eczema blockbuster-to-be Dupixent

Analyst: Payer hurdles hit dispense rates on Sanofi and Regeneron's eczema blockbuster-to-be Dupixent

Fierce Pharma

Flag link:

Just what Sanofi and Regeneron wanted: A Dupixent rollout so zippy, it's fueling bigger sales forecasts

Just what Sanofi and Regeneron wanted: A Dupixent rollout so zippy, it's fueling bigger sales forecasts

Fierce Pharma

Flag link:

Sanofi Genzyme hit with patent lawsuit over new eczema drug

Sanofi Genzyme hit with patent lawsuit over new eczema drug

Bizjournals.com

Flag link:

Regeneron's Game-Changing New Eczema Drug Could Be a Blockbuster

Regeneron's Game-Changing New Eczema Drug Could Be a Blockbuster

Motley Fool

Flag link:

Can a $37,000 price be right? For Dupixent, analysts (and one payer) say yes

Can a $37,000 price be right? For Dupixent, analysts (and one payer) say yes

Fierce Pharma

Flag link:

FDA approves Regeneron, Sanofi $37,000 per year eczema drug

FDA approves Regeneron, Sanofi $37,000 per year eczema drug

Yahoo/Reuters

Flag link:

Crunch week looms for Sanofi, Roche and GSK at U.S. drugs agency

Crunch week looms for Sanofi, Roche and GSK at U.S. drugs agency

Yahoo/Reuters

Flag link:

Sanofi, Regeneron Sue Amgen to Avoid Dupixent Patent Claims

Sanofi, Regeneron Sue Amgen to Avoid Dupixent Patent Claims

Investopedia

Flag link:

Sanofi, Regeneron say latest Dupixent eczema drug tests positive

Sanofi, Regeneron say latest Dupixent eczema drug tests positive

Yahoo/Reuters

clinical trials

Flag link:

Novartis bags a new eczema drug, builds dermatology pipeline with Ziarco buyout

Novartis bags a new eczema drug, builds dermatology pipeline with Ziarco buyout

Endpoints

Flag link:

Pages